We performed a single-center retrospective cohort study. Our study population included patients who were diagnosed with lymphoma and submitted to autologous HSCT at the Centro Hospitalar Universitário Lisboa Norte, EPE (CHULN) between January 2005 and December 2015. As exclusion criteria we defined: Patients under the age of 18 years, patients with CKD already on renal replacement therapy; patients who underwent renal replacement therapy one week before transplantation and those with previous HSCT.
The conditioning regimens used followed institutional protocols – Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) or Thiotepa, Etoposide, Cytarabine and Melphalan (TEAM). Total body irradiation is not available in our institution, and it is not contemplated in any of our institutional protocols.
Our data collection was based on registers of daily medical records, 6-h period nurses’ records and diagnostic exams during hospital admission period for HSCT, as well as all routine medical records and laboratorial analysis before and after HSCT. We collected variables related to patient demographic characteristics (age, gender, race, body weight, and height), related to patient comorbidities (diabetes mellitus, hypertension, arrythmia, valvular heart disease, ischemic heart disease, cerebrovascular disease, chronic liver disease, intestinal inflammatory disease, peptic ulcer, connective tissue disease, chronic obstructive pulmonary disease, and solid-organ cancer, psychiatric disease), related to lymphoma and previous treatment approach (subtype of lymphoma, number of previous lines of therapy, and exposure to radiotherapy in the past); related to HSCT (conditioning regimen, cells source, period of aplasia, length of stay in hospital, blood results on hospital admission day for HSCT, sinusoidal obstructive syndrome, thrombotic microangiopathy, sepsis, nephrotoxic drugs, shock, cytomegalovirus infection, AKI, and AKI stage) and related to prognostic impact (time to relapse, time to all-cause mortality and eGFR 1 year after HSCT and 3 years after HSCT).
All patients were followed until death or censored at 36 months (3 years) after HSCT. This timeline was defined because patients are often transferred to other hospitals closer to their residence for continued follow-up after this 3-year period.
The conditioning regimens used followed institutional protocols – Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) or Thiotepa, Etoposide, Cytarabine and Melphalan (TEAM). Total body irradiation is not available in our institution, and it is not contemplated in any of our institutional protocols.
Our data collection was based on registers of daily medical records, 6-h period nurses’ records and diagnostic exams during hospital admission period for HSCT, as well as all routine medical records and laboratorial analysis before and after HSCT. We collected variables related to patient demographic characteristics (age, gender, race, body weight, and height), related to patient comorbidities (diabetes mellitus, hypertension, arrythmia, valvular heart disease, ischemic heart disease, cerebrovascular disease, chronic liver disease, intestinal inflammatory disease, peptic ulcer, connective tissue disease, chronic obstructive pulmonary disease, and solid-organ cancer, psychiatric disease), related to lymphoma and previous treatment approach (subtype of lymphoma, number of previous lines of therapy, and exposure to radiotherapy in the past); related to HSCT (conditioning regimen, cells source, period of aplasia, length of stay in hospital, blood results on hospital admission day for HSCT, sinusoidal obstructive syndrome, thrombotic microangiopathy, sepsis, nephrotoxic drugs, shock, cytomegalovirus infection, AKI, and AKI stage) and related to prognostic impact (time to relapse, time to all-cause mortality and eGFR 1 year after HSCT and 3 years after HSCT).
All patients were followed until death or censored at 36 months (3 years) after HSCT. This timeline was defined because patients are often transferred to other hospitals closer to their residence for continued follow-up after this 3-year period.
Free full text: Click here
